Breast cancer and eye disease are expected to cost 11 economies in the Asia-Pacific region a combined $180 billion, according to Healthcare Asia Magazine. The outlet reported the figure on Monday, September 28, 2026.
The report frames the two conditions as a shared financial burden across the named economies rather than an issue confined to any single market. Healthcare Asia Magazine did not, in the material available, break the total down by country or by condition, nor did it specify the time period over which the costs are expected to accrue.
The $180 billion figure covers both direct and indirect costs associated with the two conditions, though the outlet's summary does not itemize those components. Breast cancer and eye disease are distinct in how they are detected, treated and managed, which means the spending they drive is likely to differ in composition across the region.
What the reporting makes clear is the scale: a nine-figure sum in the billions, spread across 11 economies. That framing places both conditions alongside other major drivers of health spending in the region, though the outlet did not offer comparisons to other disease categories.
For now, the headline number is the main takeaway. The breakdown behind it — which economies carry the largest share, how much is treatment versus lost productivity, and whether the projection covers a single year or a longer horizon — has not been disclosed in the available reporting.
Watch for follow-up coverage from Healthcare Asia Magazine with country-level figures and the methodology behind the $180 billion estimate.
